FRIDAY, Oct. 22 (HealthDay News) -- A minor lipoprotein-associated protein currently being studied in mice, and designated Apolipoprotein A-V (apoA-V), shows potential as a future treatment for humans with severe hypertriglyceridemia (HTG), according to research published online Oct. 21 in Arteriosclerosis, Thrombosis, and Vascular Biology.
Xiao Shu, of the University of California in Berkeley, and colleagues conducted a study using genetically engineered mouse models of severe HTG, including apoav−/− and gpihbp1−/− mice, to determine if the injection of apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) might have a therapeutic role in treatment of HTG when delivered intravenously.
Mice that were injected with apoA-V rHDL had a 60 percent decrease in plasma triacylglycerol (TG) at four hours, which the researchers attributed to enhanced catabolism/clearance of very-low-density lipoprotein. Site-specific mutations in the mice gene attenuated this effect by 50 percent. ApoA-V rHDL injected into gpihbp1−/− mice resulted in no significant change in plasma TG.
"In summary, we show that intravenous delivery of apoA-V has a profound TG-lowering effect in apoav−/− mice. Given that the effective dose is exceptionally low, parenteral administration of apoA-V may have potential therapeutic value for treating severe HTG in humans," the authors conclude.
Abstract
Full Text (subscription or payment may be required)
